Next Article in Journal
Aberrant Activity of Histone–Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis
Next Article in Special Issue
Competing Endogenous RNA Networks as Biomarkers in Neurodegenerative Diseases
Previous Article in Journal
Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat
Previous Article in Special Issue
Early CSF Biomarkers and Late Functional Outcomes in Spinal Cord Injury. A Pilot Study
Review

Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway

1
MTA-SZTE, Neuroscience Research Group, Semmelweis u. 6, H-6725 Szeged, Hungary
2
Department of Neurology, Interdisciplinary Excellence Centre, Faculty of Medicine, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(24), 9338; https://doi.org/10.3390/ijms21249338
Received: 12 November 2020 / Revised: 28 November 2020 / Accepted: 29 November 2020 / Published: 8 December 2020
(This article belongs to the Special Issue Peripheral Biomarkers in Neurodegenerative Diseases 2.0)
Neurodegenerative diseases are multifactorial, initiated by a series of the causative complex which develops into a certain clinical picture. The pathogenesis and disease course vary from patient to patient. Thus, it should be likewise to the treatment. Peripheral biomarkers are to play a central role for tailoring a personalized therapeutic plan for patients who suffered from neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, among others. Nevertheless, the use of biomarkers in clinical practice is still underappreciated and data presented in biomarker research for clinical use is still uncompelling, compared to the abundant data available for drug research and development. So is the case with kynurenines (KYNs) and the kynurenine pathway (KP) enzymes, which have been associated with a wide range of diseases including cancer, autoimmune diseases, inflammatory diseases, neurologic diseases, and psychiatric disorders. This review article discusses current knowledge of KP alterations observed in the central nervous system as well as the periphery, its involvement in pathogenesis and disease progression, and emerging evidence of roles of microbiota in the gut-brain axis, searching for practical peripheral biomarkers which ensure personalized treatment plans for neurodegenerative diseases. View Full-Text
Keywords: neurodegenerative disease; Alzheimer’s disease; Parkinson’s disease; amyotrophic lateral sclerosis; Huntington’s disease; multiple sclerosis; tryptophan; kynurenines; biomarkers; personalized medicine neurodegenerative disease; Alzheimer’s disease; Parkinson’s disease; amyotrophic lateral sclerosis; Huntington’s disease; multiple sclerosis; tryptophan; kynurenines; biomarkers; personalized medicine
Show Figures

Figure 1

MDPI and ACS Style

Török, N.; Tanaka, M.; Vécsei, L. Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway. Int. J. Mol. Sci. 2020, 21, 9338. https://doi.org/10.3390/ijms21249338

AMA Style

Török N, Tanaka M, Vécsei L. Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway. International Journal of Molecular Sciences. 2020; 21(24):9338. https://doi.org/10.3390/ijms21249338

Chicago/Turabian Style

Török, Nóra, Masaru Tanaka, and László Vécsei. 2020. "Searching for Peripheral Biomarkers in Neurodegenerative Diseases: The Tryptophan-Kynurenine Metabolic Pathway" International Journal of Molecular Sciences 21, no. 24: 9338. https://doi.org/10.3390/ijms21249338

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop